The therapeutic effects of TAs on CS-induced COPD inflammation may be associated with the modulation of CS-mediated AMPK/Nrf2 and NFκB/iNOS signaling pathways. The gene discussed is NFE2L2; the disease is chronic obstructive pulmonary disease.